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Abstract 1 
Background: While anosmia is common after Traumatic Brain Injury(TBI) 2 
(prevalence 4-68%),studies differ in the associations found with other variables. 3 
Aims: to assess the incidence of anosmia within a large, mixed TBI cohort and 4 
examine relationships with other injury or demographic features, including 5 
depression and global outcome(GOSE). 6 
Design, Subjects and Setting: 774 consecutive TBI admissions over two years, 7 
assessed within a specialist neurorehabilitation clinic. 8 
Methods: All patients assessed at 6-8 weeks and 1 year. Tools included the 9 
Extended Glasgow Outcome Scale(GOSE), Rivermead Head Injury Follow-up 10 
Questionnaire, Rivermead Post-Concussion Symptoms and the Hospital Anxiety and 11 
Depression Score. Olfactory function assessed with sensitivity to coffee granules. 12 
Results: The overall incidence of anosmia was 19.7%; mild TBI(9.55%), 13 
moderate(20.01%), severe(43.5%). On a logistic regression, features of TBI severity 14 
(p<0.001 (95% CI 0.098-0.438)), medical comorbidities (p=0.026 (95% CI 0.301-15 
0.927)) and depression (p=0.006 (95% CI 1.202-2.981)) were significant. 60% of 16 
patients with anosmia at one year were found to be clinically depressed, compared 17 
to 36% of patients without anosmia. 18 
Conclusion: In the largest prospective study of post-TBI anosmia, the incidence 19 
increased with TBI severity and other medical illness. The presence of anosmia 20 
should also raise the clinical suspicion of depression.21 
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Introduction 1 
Traumatic Brain Injury (TBI) is a common cause of severe disability worldwide, often 2 
affecting a disproportionate number of young individuals. It is often referred to as a 3 
µVLOHQW HSLGHPLF¶ due to the relatively low priority that the condition receives in the 4 
media.1,2 Although  incidence as high as 790/105  is reported3 the incidence of TBI 5 
resulting in hospitalisation is much lower and estimated at 235/105.1, These cases 6 
represent more significant injuries which remain the focus of most TBI studies. 7 
TBI is associated with a number of physical, psychological and social sequelae. 8 
Significant physical sequelae include: headache, pain, sensory disturbance, seizures 9 
and dizziness.4  10 
Another common complication of TBI is Olfactory Disturbance (OD). OD may occur 11 
after damage to either the peripheral or the central pathways of olfactory system. 12 
The olfactory bulb and the olfactory nerves are at risk of damage due to shearing 13 
forces induced by acceleration-deceleration injuries (Figure 1). Damage to 14 
secondary olfactory centres such as the orbitofrontal cortex is also possible (Figure 15 
2).12   As OD usually manifests with frontal lobe pathology, it can be part of a 16 
complex clinical picture with other frontal lobe functions including cognitive 17 
impairment and depression.9,13-14 18 
OD can be further categorised as significant loss of function (anosmia) as opposed 19 
to lesser degrees of olfactory loss (hyposmia) although other disorders such as 20 
altered sense of smell (parosmia) also exist. The clinical significance of hyposmia is 21 
unclear and many individuals are completely unaware of subtle changes in olfactory 22 
perception.5 Furthermore, the wide range of available olfactory tests differ in their 23 
threshold for diagnosing OD, particularly hyposmia.6,7 In part due to such differences 24 
in classification, as well as marked differences between the tests, the incidence of 25 
OD is unclear and ranges between 4-60%.8-11  26 
 27 
Previous studies of OD differ considerably in methodology. This is particularly 28 
marked with regards to the recruitment of subjects. Many studies have very selected 29 
populations such as referrals to psychiatry or litigants. Furthermore there are wide 30 
variations in the established olfactory tests with different tests, number of items and 31 
varying thresholds. Unsurprisingly this has resulted in considerable variation in 32 
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estimated incidence of OD.  1 
As a result of this uncertainty and because anosmia affects quality of life and can be 2 
associated with other frontal lobe dysfunction9,33, the rationale of this study was  to 3 
assess the incidence of OD and whether any associated injury or demographic 4 
features could be identified. This was examined in a large mixed TBI population, 5 
representative of hospitalized cases and therefore of clinical relevance to all health 6 
professionals in TBI.  However an attempt was made to identify only clinically 7 
significant OD rather than sub-clinical levels of dysfunction such as hyposmia, whose 8 
significance is unclear. Hence the term anosmia is preferred to terms such as OD or 9 
hyposmia. This was identified with a single strong smell (coffee) which is quick and 10 
easy to perform and which has been validated in TBIy43 Associations of anosmia 11 
with population and injury features were also sought. No a priori hypotheses were 12 
made as to the variables that may form associations with OD in order to avoid any 13 
potential bias in study. It was hoped that any positive findings would help to inform 14 
clinicians and individuals of the likely risk factors, prevalence and possible prognosis. 15 
 16 
Methods 17 
The SHEFBIT (Sheffield Brain Injury after Trauma) cohort is a large outcome study 18 
of adult TBI patients admitted to a large teaching hospital and assessed and treated 19 
by a Rehabilitation Medicine team in outpatients. It is a prospective, observational 20 
cohort, encompassing the full spectrum of severity and aetiology of TBI and 21 
represents the condition as seen and treated by clinicians worldwide.15  22 
Patients admitted with TBI between August 2013 and July 2015 were screened for 23 
inclusion.  Eligible participants had a minimum of one QLJKW¶V stay in hospital and a 24 
CT brain scan.  Exclusion criteria included children (<17) (seen at a separate 25 
hospital), previous TBI requiring hospital admission, dementia or residence out of 26 
Region.  There was no upper age restriction. The diagnosis of TBI was confirmed 27 
using the Common Data Elements criteria.16 28 
Admitted patients were screened within 24 hrs by the rehabilitation liaison team or 29 
the lead author (RS). Follow-up clinic appointments for TBI rehabilitation were 30 
arranged for 9-12 weeks after injury in the Brain Injury clinic, run by a Consultant in 31 
Rehabilitation Medicine(RS). All patients were subsequently followed up at 1 year to 32 
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measure outcomes including psychosocial outcome, depression and anosmia. Only 1 
assessments at 1 year are used in the study. Patients received letters, a text 2 
message and a phone call from clinic staff to facilitate attendance at 1 year. Non-3 
attenders were telephoned to re-arrange appointments. All clinic patients were seen 4 
by the same clinician (RS). Records were examined for information on injury 5 
features, such as Glasgow Coma Score(GCS) on admission and head CT findings. 6 
Demographic factors including employment and family support were recorded as 7 
well as past medical and psychiatric histories. The latter was defined by any episode 8 
with psychiatrist, clinical psychologist or diagnosis by general practitioner. Alcohol 9 
intoxication at time of injury was taken from patient history or ambulance/medical 10 
records from admission. 11 
Mechanism of TBI was classified according to the Trauma Audit and Research 12 
Network (TARN) classification system as falls, assault, road traffic collisions (RTC) 13 
and other mechanisms which predominantly consisted of work place injuries, sports 14 
injuries and falls greater than 2 metres.17 CT scan findings were documented with 15 
location and type of each lesion. Only initial scan was used in case of repeat scans 16 
being taken. Scans were classified using the ³RYHUDOO DSSHDUDQFH´ of the CT scan 17 
which grades the severity of CT abnormalities after TBI; these are graded as normal, 18 
mild focal injury, medium focal injury and diffuse injury.18  Medical comorbidity was 19 
assessed with the Cumulative Illness Rating Scale (CIRS) with a cut off >10 20 
establishing significant level of comorbidity.19 Pre-injury employment status was 21 
recorded as working (including full-time students), unemployed or retired. Work 22 
status at follow-up was recorded in three categories; unable to work, partial return to 23 
work and a complete return to work or the capacity for work for those who were 24 
retired or unemployed. The study was approved by both the Hospital Trust 25 
(STH16208) and the University of Sheffield Ethics Committees (Ref008315). 26 
Assessments 27 
Anosmia was described as a binary outcome and function was tested by a brief 28 
assessment of odour identification with coffee granules in a container with holes to 29 
avoid identification. Granules were changed at each clinic and held directly under the 30 
nose.  Patients who reported no change in olfactory function and were able to 31 
correctly identify coffee were described as µQRUPRVPLF¶ whereas those  who were 32 
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unable to identify the coffee were described as having anosmia, irrespective of their 1 
self-report.  It is acknowledged that there are a number of different methods of 2 
defining degrees of OD which is discussed later. However single odour identification 3 
with self-report has been shown to be reliable and is the standard technique taught 4 
in textbooks of neurology and medicine.20,40-42 Our parallel study confirms that coffee 5 
produces similar result to a validated test (Sniffin Sticks) with a sensitivity of 93% 6 
and specificity 96%. More detailed tests take considerable time and in a busy clinic 7 
are not possible. This was a pragmatic approach to recognizing significant 8 
impairment of olfactory function although we recognize that it is not perfect.  9 
Depression was assessed using the HADS (Hospital Anxiety and Depression Scale). 10 
This is a self-filled questionnaire with seven questions for both anxiety and 11 
depression resulting in an overall score of 0-21 for each.22 Only the depression 12 
subscale was used.Patients also completed a Rivermead Head Injury Follow-up 13 
Questionnaire and a Rivermead Post-concussion Symptom Score.  The former is a 14 
ten item questionnaire for psychosocial function after TBI and the latter is a 15 
commonly used checklist of sixteen common head injury symptoms graded in Likert 16 
style from 0-4.  Both of these have been validated in TBI populations.23,24 Overall 17 
global outcome was assessed by structured interview using the Extended Glasgow 18 
Outcome Scale (GOSE).25 19 
Analysis 20 
Patients with/without anosmia at follow-up were compared for demographic and 21 
injury variables using a univariable regression for continuous variables such as age 22 
or Ȥ2-test for categorical variables such as employment or socioeconomic class. 23 
When Ȥ2-test assumptions were not met, a Fisher Exact test was used.  Further 24 
analysis was carried out with a multivariable logistic regression analysis with 25 
anosmia as the outcome of interest and variables entered to determine the 26 
independent predictors of anosmia. Significance level was taken as p<0.05. 27 
Statistical analysis was performed using SPSS version 23. 28 
29 
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Results 1 
 2 
Patient Demographics 3 
A total of 774 patients were enrolled into the study; 690 patients completed the one 4 
year follow up. Despite calls and letters, 46 individuals did not attend follow-up and 5 
38 had died. This represents a follow-up of 94% of the study. The demographics of 6 
patients who completed both appointments are shown in Table 1 compared to those 7 
who were lost to follow-up. Individuals lost to follow up were older by 7 years and 8 
had slightly milder TBI but otherwise showed no major difference to those who 9 
attended follow-up. 10 
Prevalence of Anosmia 11 
The primary outcome of this study was to measure the prevalence of anosmia within 12 
a mixed TBI population. At twelve months post-injury this was 19.7% (n=136). Three 13 
individuals could not smell the granules due to a common cold and were considered 14 
normosmic. The prevalence of anosmia was lowest in patients with mild TBI (9.55%) 15 
followed by moderate TBI (22.01%) and highest in those with severe injuries 16 
(43.5%). 17 
Univariable Analysis 18 
Within a univariable analysis, a number of factors were found to be significant (p 19 
<0.05): TBI severity, (p<0.001); Previous Psychiatric History, (p=0.011); GCS at time 20 
of injury, (p<0.001); CT Scan Appearance (p<0.001); intoxication at the time of the 21 
injury (p<0.001); medical comorbidity (p=0.010); depression and anxiety at twelve 22 
months follow up (p<0.001),(p<0.001); GOSE at twelve months (p<0.001), RHFUQ 23 
and RPCS scores at twelve months (p<0.001),(p<0.001). Employment status at 24 
twelve months post-injury was also significant (p<0.001), as a large proportion of 25 
patients failed to return to work to the same standard as before TBI. Aetiology of TBI, 26 
gender, ethnicity and pre-injury employment status were not significant. The 27 
univariable p-values are shown in the first column of Table 2. 28 
Multivariable Analysis 29 
A multivariable logistic regression was conducted to analyse the impact of all the 30 
variables assessed within the study. For this analysis, GCS was used as the marker 31 
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of severity. Anosmia was the dependent variable. The results are shown in Table 2 1 
with 95% confidence intervals.  2 
Significant relationships were found with comorbidity (p=0.026); depression at twelve 3 
months (p=0.006) and TBI severity (p<0.001). All other variables dropped out of the 4 
final model. 5 
The overall model was highly significant (p<0.001), Nagelkerke R2 was 0.271. The 6 
model correctly classified the outcome in 83.0% of cases compared to the model 7 
with no predictors that classified 80%. While this is a small improvement, it is a 8 
significant one. The AUC was 0.806 (95%CI 0.768-0.841). The Hosmer-Lemeshow 9 
Goodness of Fit statistic was satisfactory Ȥ2=5.765, df8, p=0.674). 10 
 11 
Discussion 12 
 13 
The incidence of anosmia was 19% although this varied markedly with severity of 14 
TBI.  This falls in the middle of the range of previous estimates which vary 15 
considerably from 4- 60%.10,11  16 
This is by far, the largest prospective study on anosmia in consecutive TBI 17 
admissions to hospital. The group is typical of the patients seen in clinical practice 18 
and therefore relevant to all clinicians. It suggests that screening for anosmia can be 19 
done simply and quickly even in busy clinics.  Apart from TBI severity, it was also 20 
found that anosmia was strongly associated with significant medical comorbidity and 21 
depression.  These findings have been reported in previous literature.  A number of 22 
variables including psychosocial outcome (RHFUQ) and global outcome (GOSE) 23 
were significant on univariable but not on multivariable testing. 24 
The differences in previous studies can in large part be attributed to wide differences 25 
in study methodologies.  In many instances, patient recruitment is limited only to 26 
STBI.  Other studies use patient self-report or are based on convenience samples 27 
such as referrals to psychiatry or ENT.  We are not aware of any study that has 28 
prospectively examined anosmia in consecutive TBI admissions in a systematic 29 
manner. 30 
The finding of increased incidence of anosmia with increasing TBI severity has been 31 
well described.11,26  In STBI, the incidence can be as high as 50% 6 and  in combined 32 
moderate and severe injuries, 35%.14  MTBI estimates vary from 4-16%.27,28 These 33 
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are similar to the findings here.  Such figures may be useful in advising patients after 1 
TBI with respect to the prognosis of long-term anosmia. 2 
However, it should be noted that some studies have shown no relationship to TBI 3 
severity.10   4 
In contrast to findings with TBI severity, there was no association with severity of CT 5 
findings and anosmia. This may reflect the inability of the classification system to 6 
specify the exact location of CT lesions rather than specifically to the frontal lobe 7 
where olfactory function is located.18 In this respect, MRI may offer better imaging 8 
than CT in the investigation of anosmia.39  9 
Medical comorbidity was an independent predictor of anosmia.  It is possible that this 10 
is subject to a number of confounding factors; several medical conditions such as 11 
Type II diabetes mellitus and hypertension have been identified as potential causes 12 
of anosmia as well as drugs such as antihypertensives.29,30 Unfortunately we have 13 
not subclassified comorbidities so cannot separate the effect of different conditions 14 
or drugs. 15 
Anosmia can be considered a manifestation of frontal lobe pathology and association 16 
between anosmia and additional frontal lobe dysfunction including verbal fluency and 17 
executive function is well documented.6,9  The results of this study, demonstrating a 18 
significant association between anosmia and depression after TBI, are of particular 19 
interest.37 This association may occur due to an anatomical relationship between the 20 
two functions. As the OFC plays a key role in mood regulation, as well as the 21 
recognition and differentiation of smell,20,31 it is likely that this shared location is at 22 
risk of damage after TBI (Figure 2). The finding cannot be explained simply by 23 
increased severity of TBI as most studies show no link of depression and TBI 24 
severity.32   25 
It is known that anosmia can be detrimental to quality of life(QOL).33  A number of 26 
TBI outcomes, although not QOL, were measured in this cohort. Unfortunately many 27 
of these factors were highly correlated with one another.  It has been shown that 28 
many outcome measures evaluate the same concept of ³HPRWLRQDO GLVWUHVV´ and can 29 
be expected to be simultaneously elevated or normal in individuals .34 This was 30 
demonstrated in the multivariable analysis where outcome measures, including 31 
GOSE, dropped out of the model, having been highly significant on univariable tests. 32 
Therefore in this study, there was no association between anosmia and global 33 
outcome.It has been suggested that the GOSE is a relatively crude measure and 34 
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may lack sufficient sensitivity to detect subtle changes. It is also possible that 1 
anosmia affects quality of life but not the actual functioning and abilities of an 2 
individual (the ³TXDQWLW\ of life´ Hence global outcome is unaffected. The use of a 3 
QOL measure would have been helpful in assessing this. 4 
   5 
Strengths and weaknesses 6 
The main strength of this project is the large size of the prospective cohort when 7 
compared to other studies.  The SHEFBIT cohort is representative of hospitalised 8 
TBI with a good mix of mild, moderate and severe TBI.16 These are sufficient 9 
numbers to make relevant inferences about the subgroups in a clinically relevant 10 
setting. Much of the previous literature is in highly selected groups e.g. referred for 11 
olfactory testing or in litigants. The results are therefore relevant to all clinicians who 12 
we hope, will be able to screen for anosmia with a simple but effective test.). 13 
Similarly, the patient assessments occurred in a setting that will be familiar to 14 
clinicians treating TBI; individuals were followed up in a specific Brain Injury Clinic 15 
shortly after injury and again at 1 year. The assessments were pragmatic in terms of 16 
the time taken to evaluate a number of clinical parameters including anosmia. It is 17 
important to minimise patient burden as extensive and detailed assessments lead to 18 
poor patient attendance and distress.35  19 
A particular strength of the study was the ability to facilitate re-attendance by use of 20 
letters and phone calls.  This undoubtedly led to an excellent follow-up rate (94%), 21 
much higher than other TBI studies where losses of up to 70% at 6 months are 22 
reported.38 23 
The use of a single observer for all assessments minimizes inter-observer variation. 24 
The main weakness of the study is the diagnosis of anosmia using coffee granules.  25 
While this is a very potent stimulus and single odour identification is the standard 26 
technique taught in textbooks of neurology and medicine 20,40-42, it is by no means 27 
the gold standard. In a parallel study we found sensitivity of 93% and specificity of 28 
96% in comparison of coffee with a 12 item Sniffin Sticks test kit; this suggests 29 
excellent validity. Indeed there is no agreement on which of the many available tests 30 
is the best and considerable variation exists.6-7,36   Unfortunately, detailed 31 
assessments using a battery of as many as 40 different smells can take up to an 32 
hour to administer and in a busy clinical setting, such assessments are  unlikely to 33 
be possible. The more detailed tests however will identify milder forms of OD such 34 
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as hyposmia which we have not done. However the clinical significance of such 1 
disorders is unclear; many patients are unaware that they have these subtle degrees 2 
of altered smell and tests vary considerably in the diagnostic threshold.5 It is also 3 
accepted that the coffee test does not detect parosmia or altered sensation although 4 
no individual reported this on testing. By contrast anosmia is a far more significant 5 
complication and it is rare for an individual with anosmia to have not noticed such a 6 
change. 7 
Other weaknesses are that smoking has not been corrected in the model and that 8 
there is no control group for the study. It was also not possible to test for taste 9 
dysfunction due to time constraints but this may have yielded further information. 10 
Future work needs to establish the nature of the relationship between anosmia and 11 
depression with particular regards to the anatomical link and frontal lobe damage. 12 
Documentation of CT abnormality needs to describe the exact location of the lesions 13 
rather than the extent of lesions.  In addition the relationship with other possible 14 
frontal lobe impairments such as executive function or verbal fluency may be 15 
conducted.  It is important to distinguish between subtle changes in smell which are 16 
often unnoticed by the individual and more significant, clinically relevant anosmia 17 
which has been investigated in this study.  Within constraints of busy clinical 18 
practice, assessment has to be reliable but practical and much of the established 19 
literature is impractical for busy clinicians. 20 
An examination of the temporal relationship between depression and development of 21 
anosmia may also allow the determination as to whether one of these features leads 22 
to the other in a particular chronology. In other words, does anosmia lead to 23 
depressed mood as a result of loss of pleasurable smells or could depression result 24 
in a blunted response to appreciation or distinguishing of smells. This will require 25 
repeated assessments of individuals and is unlikely to be achieved in a cohort of this 26 
size. 27 
The ease of testing and the accuracy of the single odour test should encourage busy 28 
clinicians to screen TBI patients for anosmia. We suggest that positive findings may 29 
then need to be referred for further detailed assessment by ENT specialists. 30 
 31 
 32 
Conclusions 33 
The incidence of anosmia was 19.7% in a mixed TBI population and was significantly 34 
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associated with TBI severity.Even in a busy clinical setting, screening for anosmia 1 
can be done quickly and accurately.  Despite often being regarded as an innocuous 2 
outcome after TBI, the relationship between anosmia and depression demonstrates 3 
the significance of anosmia within the clinical picture of TBI and the relationship with 4 
overall outcome requires further exploration. 5 
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Table 1: Demographics of study cohort and non-attenders at 1 year 40 
Figures are number(%) for categories and mean(95% Confidence Interval) for continuous data except 41 
Length of stay, expressed as median (interquartile range) *p<0.05 42 
 43 
 44 
 45 
 46 
 47 
 48 
Table 1; demographics at 1 year and comparison to non-attenders 
 Followed up, n= 
690 
lost at follow-up, 
n=46 
ʖ2  or t-test, df, p-
value 
Mean Age yrs (95% CI) 46.5(45.6-48.3) 53.2(46.2-55.8) 5.39 df825 p=0.022* 
Gender    
Male N(%) 484 (70.1%) 28(60.9) 1.56 df1 p=0.212 
Ethnicity N(%)    
White 641 (92.9) 44 (95.7) 2.116 df4 p=0.714 
(Fisher Exact Test) South Asian 33 (4.8) 2 (4.3) 
Black 11 (1.6) 0 (0) 
Oriental 3 (0.4) 0 (0) 
Other 2 (0.3) 0 (0) 
(Non-white) 49 (7.1) 2 (4.3) 0.508 df1 p=0.510 
Employment N(%)    
Yes 488 (70.7) 26 (56.5) 5.22 df2 p=0.074 
No 96 (13.9) 5 (10.9) 
Retired 106 (15.4) 15 (32.6) 
Aetiology N(%)    
Fall 233 (33.8) 13 (28.3) 3.4 df4 p=0.494 
RTC 187 (27.1) 15 (32.6) 
Assault 137 (19.9) 6 (13.0) 
Sport 48 (7.0) 4 (8.7) 
Other(work) 85 (12.3) 8 (17.4) 
Any Comorbidity N (%) 249 (32.2) ? 12 (26.1) 2.83 df1 0.092 
Alcohol at injury N (%) 206 (26.6) 13 (24.5) 0.111 df1 0.739 
Previous Psychiatric Hx    
N (%) 
152 (22.0) 9 (19.6) 0.148 df1 0.701 
Mean GCS at injury 11.9(11.7-12.1) 12.9(12.3-13.6) 3.26 df825 0.013* 
Severity by GCS N(%)    
Severe(3-8) 108 (15.7) 7 (13.2) 0.609 df2 p=0.738 
Moderate(9-12) 268 (38.8) 19 (35.8) 
Mild(13-15) 314 (45.5) 27 (50.9) 
Median Length of Stay in 
Days (IQR) 
3.0 (8) 2.0 (7) U=19639, p=0.597 
(Mann-Whitney 
Test) 
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Table 2. Univariable and Multivariable Analysis of anosmia 
     95% CI for OR 
Variable Univariable 
p-value1 
B Multivariable 
p-Value 
OR Lower Upper 
Gender  0.260 0.337 0.197 1.401 0.839 2.339 
Ethnicity (White) 0.463 -0.636 0.116 0.530 0.240 1.169 
Age 0.710 -0.001 0.944 0.992 0.982 1.017 
Aetiology  0.088  0.258    
Fall(baseline)   - 1   
 RTC  0.737 0.079 2.089 0.917 4.756 
 Assault  0.461 0.242 1.586 0.732 3.437 
Sport   0.970 0.028 2.637 1.110 6.268 
Other   0.550 0.343 1.734 0.557 5.403 
Alcohol <0.001* 0.203 0.458 1.225 0.717 2.091 
Psychiatric History 0.011* 0.048 0.857 1.049 0.622 1.768 
Pre-injury Job 0.072  0.936    
Employed(base)   - 1   
Unemployed  -0.105 0.815 0.900 0.373 2.173 
Retired  -0.006 0.990 0.994 0.370 2.671 
CT Scan <0.001*  0.297    
NAD(baseline)   - 1   
Focal  -0.062 0.895 0.940 0.374 2.362 
Adjacent Lobes  0.541 0.194 1.717 0.760 3.881 
Diffuse  0.154 0.677 1.167 0.565 2.413 
Comorbidity 0.010* 0.590 0.026* 1.893 1.202 2.981 
Return to work <0.001*  0.311    
Full(baseline)   - 1   
Partial  0.680 0.143 1.974 0.795 4.906 
No work  0.555 0.150 1.741 0.818 3.707 
GCS <0.001* -0.265 <0.001* 0.796 0.713 0.889 
HADS-D <0.001* 0.152 <0.001* 1.164 1.012 1.422 
RHFUQ <0.001* 0.003 0.869 1.003 0.963 1.045 
RPCS <0.001* 0.013 0.464 1.013 0.979 1.048 
GOSE <0.001* -0.229 0.203 0.795 0.559 1.132 
Constant  1.907 0.259 6.733   
 5 
Table 2; Univariable and Multivariable Analysis of anosmia 6 
1
 univariable regression for continuous and Ȥ-test for categorical variables. * significant at p<0.05 7 
 8 
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